Who is sponsoring NCT02797561?

NCT02797561 is sponsored by Seung-Jung Park.

What drugs are being tested in NCT02797561?

Interventions in NCT02797561: 5 year Follow-up.

What condition does NCT02797561 study?

NCT02797561 studies Percutaneous Transluminal Coronary Angioplasty.

Is NCT02797561 still recruiting?

NCT02797561 is currently terminated. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT02797561: IRISFFRTandem

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of FFR Guided Percutaneous Coronary Intervention in Coronary Tandem Lesions

Terminated Last updated 15 April 2026

What this trial tests

trial testing 5 year Follow-up in Percutaneous Transluminal Coronary Angioplasty in 438 participants. Terminated before completion.

Timeline

25 July 2016

Primary endpoint
13 April 2026

13 April 2026

Quick facts

Lead sponsor	Seung-Jung Park
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	438
Start date	25 July 2016
Primary completion	13 April 2026
Estimated completion	13 April 2026
Sites	12 locations across South Korea

Drugs / interventions tested

5 year Follow-up

Conditions studied

Percutaneous Transluminal Coronary Angioplasty — all drugs for Percutaneous Transluminal Coronary Angioplasty →

Sponsor

Seung-Jung Park — full company profile →

Who can join

19 and older, any sex, with Percutaneous Transluminal Coronary Angioplasty. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effect of FFR (Fractional flow reserve) guided Percutaneous Coronary Intervention in coronary tandem lesions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Percutaneous Transluminal Coronary Angioplasty

Currently open trials in the same condition.

NCT05972070 — Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence · recruiting
NCT03209414 — Frailty Syndrome in Daily Practice of Interventional Cardiology Ward · recruiting

Other Seung-Jung Park trials

Trials by the same sponsor.

NCT06908499 — The DECISION-CTO Extended 10 Y Follow-up · not yet recruiting
NCT06177743 — IRIS-Coroflex NEO Cohort · recruiting
NCT05125367 — Ten-Year Outcomes of Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation i · completed
NCT03967158 — Evaluation of Effectiveness and Safety of XIENCE Sierra in Routine Clinical Practice · active not recruiting
NCT03190057 — IRIS-BioFreedom Cohort in the IRIS-DES Registry · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02797561 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seung-Jung Park
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02797561.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing